Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials

What is it about?

Background • There is a need for appropriate treatment and supportive care in Asian patients with breast cancer. • There are limited data from randomized controlled trials of G-CSF performed in Asian patients with breast cancer. Results • In Asian patients with breast cancer receiving myelosuppressive chemotherapy, LA-EP2006 was equivalent to reference pegfilgrastim in terms of duration of severe neutropenia in Cycle 1. • Similar safety profiles were reported in patients receiving LA-EP2006 and in those receiving reference pegfilgrastim. • No anti-pegfilgrastim neutralizing antibodies were detected. Discussion • Data were similar to the overall population of the PROTECT study and in line with those reported in Asian patients with breast cancer receiving an equivalent dose of GCSF.

Featured Image